STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRMD
  4. [Form 4] MARIMED INC. Insider Trading Activity

MariMed (MRMD) CEO Jon Levine Converts 93,750 RSUs, Updates Share Holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported equity transactions dated 11/29/2025. He exercised 93,750 restricted stock units (RSUs), which converted into the same number of common shares at an exercise price of $0, and then had 27,516 shares of common stock withheld at $0.0896 per share to cover tax obligations related to the RSU vesting.

After these transactions, Levine directly beneficially owns 21,072,715 shares of MariMed common stock and has an additional 6,684,640 shares held indirectly through the Jon Levine Family Trust, for which he disclaims beneficial ownership. He also continues to hold 187,500 RSUs, from a grant made on November 29, 2024, that are scheduled to vest in four equal installments between May 29, 2026 and November 29, 2027.

Positive

  • None.

Negative

  • None.
Insider Levine Jon R
Role President and CEO
Type Security Shares Price Value
Exercise Restricted Stock Units (RSU) 93,750 $0.00 --
Exercise Common stock 93,750 $0.00 --
Tax Withholding Common stock 27,516 $0.0896 $2K
holding Common stock -- -- --
Holdings After Transaction: Restricted Stock Units (RSU) — 187,500 shares (Direct); Common stock — 21,100,231 shares (Direct); Common stock — 6,684,640 shares (Indirect, By the Jon Levine Family Trust)
Footnotes (1)
  1. RSUs convert to shares of common stock on a one-for-one basis. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These RSUs were granted on November 29, 2024; the remaining RSUs under this grant will vest in four equal installments, on each of May 29, 2026, November 29, 2026, May 29, 2027 and November 29, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Levine Jon R
(Last) (First) (Middle)
C/O MARIMED INC.
10 OCEANA WAY
(Street)
NORWOOD, MA 02062
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 11/29/2025 M 93,750 A $0(1) 21,100,231 D
Common stock 11/29/2025 F 27,516(2) D $0.0896 21,072,715 D
Common stock 6,684,640 I By the Jon Levine Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 11/29/2025 M 93,750 (4) (4) Common Stock, par value $.001 per share 93,750 $0 187,500 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
4. These RSUs were granted on November 29, 2024; the remaining RSUs under this grant will vest in four equal installments, on each of May 29, 2026, November 29, 2026, May 29, 2027 and November 29, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Jon R. Levine 12/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did MariMed (MRMD) CEO Jon Levine report in this Form 4 filing?

Jon R. Levine, President, CEO, director and 10% owner of MariMed Inc. (MRMD), reported the conversion of 93,750 RSUs into common stock and the withholding of 27,516 shares to satisfy tax obligations on 11/29/2025.

How many restricted stock units did Jon Levine exercise and at what price?

Levine exercised 93,750 restricted stock units (RSUs), which converted to an equal number of MariMed common shares at an exercise price of $0 per share, as disclosed in the filing.

How many MariMed (MRMD) shares were withheld for Jon Levines taxes?

The filing states that 27,516 shares of MariMed common stock were withheld by the issuer to satisfy Levines tax withholding obligations in connection with the vesting of RSUs, at a price of $0.0896 per share.

What is Jon Levines MariMed share ownership after these transactions?

After the reported transactions, Levine directly beneficially owns 21,072,715 shares of MariMed common stock and 6,684,640 shares are held indirectly through the Jon Levine Family Trust, for which he disclaims beneficial ownership.

What RSU balance does Jon Levine still hold at MariMed (MRMD)?

Following the exercise, Levine continues to hold 187,500 RSUs. These RSUs were granted on November 29, 2024 and remain outstanding as derivative securities beneficially owned directly.

What is the vesting schedule for Jon Levines remaining RSUs at MariMed?

The remaining RSUs from the November 29, 2024 grant will vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027, and November 29, 2027, according to the award agreement.

How are the MariMed shares in the Jon Levine Family Trust treated in this filing?

The filing explains that 6,684,640 shares are held in the Jon Levine Family Trust for the benefit of Levines spouse and children, and that he disclaims beneficial ownership of these securities.